SUBSCRIBE
SUBSCRIBE

Immune-Onc Therapeutics

NEWS
What You Need to Know About Immune-Onc Therapeutic
Business
What You Need to Know About Immune-Onc Therapeutics
Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.
December 13, 2017
 · 
5 min read
 · 
Mark Terry
NextGen Bio Class of 2018
Bio NC
Top 20 Life Science Startups to Watch in 2018
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
December 4, 2017
 · 
9 min read
 · 
Mark Terry
AWARDS
  • NextGen Class of 2018
JOBS
IN THE PRESS
Press Releases
Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche
February 27, 2025
 · 
6 min read
Press Releases
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting
December 9, 2024
 · 
7 min read
FDA
Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020
November 10, 2020
 · 
6 min read
Biotech Bay
Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020
November 9, 2020
 · 
4 min read
Drug Development
Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia
September 16, 2020
 · 
4 min read
Biotech Bay
Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4
August 4, 2020
 · 
4 min read
FDA
Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance
May 29, 2020
 · 
3 min read
Business
Company Profile for Immune-Onc Therapeutics, Inc.
November 21, 2019
 · 
1 min read
Business
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions
November 19, 2019
 · 
8 min read
Business
Immune-Onc Therapeutics Announces Key Executive Appointments and Series B Funding
September 18, 2018
 · 
5 min read
Load More